PTIX Protagenic: ערך חשבונאי למניה

The book value per share of Protagenic Therapeutics (PTIX) reflects the dynamics of equity, while -2.44 characterizes this valuation parameter. A neutral geopolitical status in the US minimizes external risks. The business model relies on outsourcing production and testing to maintain flexibility. ESG principles are integrated into peptide development through strict bioethics and data security controls.

This indicator reflects the difference between total assets and liabilities, allowing investors to assess the real value of capital devoid of market speculation. Analyzing the book value per share helps identify hidden write-downs, which is particularly critical for Protagenic Therapeutics (PTIX), where conservative cash management and stable leadership minimize the risks of sudden liquidity loss.